- New York-based global growth equity venture capital (VC) firm, General Atlantic, is investing $100 million in Mumbai-based contract research and drug delivery company Rubicon Research Pvt.
- With this investment from General Atlantic, Rubicon intends to focus its efforts on bringing to market innovative medicines to solve fundamental patient needs through the use of its proprietary drug delivery technologies, as well as increase its manufacturing footprint across the world.
- Rubicon holds more than 50 issued patents in drug delivery technologies and with its new R&D centre can develop pharmaceutical products across dosage forms.
With $100 Mn from General Atlantic, India's Rubicon Research to Back Early/Seed Stage Startups in Pharma Sector
8 April 2019 1:08 PM GMT